Sfoglia per AUTORE
PRESSIANI T
Collezione AO Ordine Mauriziano

  

Items : 3

Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial. in ESMO open / ESMO Open. 2025 Feb;10(2):104110. doi: 10.1016/j.esmoop.2024.104110. Epub 2025 Jan 27.

2025
AO Ordine Mauriziano

Piscaglia F; Masi G; Martinelli E; Cabibbo G; Di Maio M; Gasbarrini A; Iavarone M; Antonuzzo L; Mazzaferro V; Ballestrero A; Garufi C; Bergamo F; Celsa C; Marino D; Tovoli F; Ponziani FR; Pressiani T; Astolfi C; Gazzoli GC; Ciardiello F; Daniele B; Rimassa L;

Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study. in BMC cancer / BMC Cancer. 2024 May 6;24(1):563. doi: 10.1186/s12885-024-12328-0.

2024
AO Ordine Mauriziano

Niger M; Nichetti F; Fornaro L; Pircher C; Morano F; Palermo F; Rimassa L; Pressiani T; Berardi R; Gardini AC; Sperti E; Salvatore L; Melisi D; Bergamo F; Siena S; Mosconi S; Longarini R; Arcangeli G; Corallo S; Delliponti L; Tamberi S; Fea E; Brandi G; Rapposelli IG; Salati M; Baili P; Miceli R; Ljevar S; Cavallo I; et alii...

A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study. in BMC cancer / BMC Cancer. 2024 Apr 8;24(1):436. doi: 10.1186/s12885-024-12225-6.

2024
AO Ordine Mauriziano

Niger M; Nichetti F; Fornaro L; Pircher C; Morano F; Palermo F; Rimassa L; Pressiani T; Berardi R; Gardini AC; Sperti E; Salvatore L; Melisi D; Bergamo F; Siena S; Mosconi S; Longarini R; Arcangeli G; Corallo S; Delliponti L; Tamberi S; Fea E; Brandi G; Rapposelli IG; Salati M; Baili P; Miceli R; Ljevar S; Cavallo I; et alii...